Treatment
Dapagliflozin clinical trials
We’re tracking 92 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT06711185RecruitingPhase 3
Can dapagliflozin protect breast cancer patients' hearts during chemo?
This trial tests if a diabetes medicine called dapagliflozin (also known as Farxiga) can protect the hearts of women with breast cancer while they receive anthracycline chemotherapy. You would take the medicine and have heart MRI scans to see if it helps prevent heart damage.
Campinas, São PauloAges 18 years+ - NCT06868797Recruiting
Dapagliflozin for advanced heart failure patients waiting for transplant
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
BronAges 18 years+ - NCT06982079RecruitingPhase 3
SGLT2 inhibitors for advanced kidney disease
This trial tests whether SGLT2 inhibitor drugs can protect kidney function in people with advanced chronic kidney disease who are not yet on dialysis. It may help slow further kidney decline.
CairoAges 18 years+ - NCT07082114RecruitingPhase 3
Testing a new tablet for type 2 diabetes
This study tests a new pill called HDM1002 for adults with type 2 diabetes. It aims to see if it helps control blood sugar when added to your current metformin treatment.
Yueyang, HunanAges 18–75 - NCT07174687RecruitingPhase 2
SGLT2 inhibitor drug for geographic atrophy in dry AMD
This trial tests whether an SGLT2 inhibitor (a diabetes drug) can help slow geographic atrophy, a type of advanced dry age-related macular degeneration. It might be an option if you have dry AMD with specific types of retinal damage and haven't had other treatments.
St Louis, MissouriAges 50 years+ - NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07222917RecruitingPhase 2
Dapagliflozin with baxdrostat for kidney disease and high blood pressure
This trial tests if adding dapagliflozin to baxdrostat (a new blood pressure drug) reduces protein in urine better than baxdrostat alone in people with chronic kidney disease and high blood pressure. It aims to find a more effective way to protect kidney health.
Surprise, ArizonaAges 18 years+ - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT07254572RecruitingPhase 4
Comparing diabetes drugs for heart health in prediabetes
This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.
WarsawAges 18–80 - NCT07273838RecruitingPhase 2
SGLT2 inhibitor for acute heart and kidney failure
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
New Haven, ConnecticutAges 18–85 - NCT07280585RecruitingPhase 3
Testing a diabetes drug to slow kidney disease progression
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
FeldkirchAges 18–60 - NCT07295223RecruitingPhase 3
GLP-1 and SGLT2 drugs for heart attack recovery
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
León, GuanajuatoAges 18 years+ - NCT07297589RecruitingPhase 3
CT scan of heart fat after heart attack
This study uses a CT scan to look at the layer of fat around the heart in people who recently had a heart attack and have type 2 diabetes and obesity. It aims to understand how this fat relates to inflammation and heart health.
León, GuanajuatoAges 18 years+ - NCT07379333RecruitingPhase 3
Testing a new drug for type 2 diabetes when metformin and dapagliflozin aren't enough
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
Gyeonggi-doAges 19 years+ - NCT07405216RecruitingPhase 4
SGLT2 inhibitors for teens with early kidney disease
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
Aguascalientes, AguascalientesAges 14–18 - NCT07491042Recruiting
A study of SGLT2 inhibitors for people on peritoneal dialysis
This study tests whether a type of diabetes medicine called SGLT2 inhibitors (which help lower blood sugar and protect the kidneys) can benefit people who are on chronic peritoneal dialysis. You may be able to join if you are 13 or older, have some urine output, and do not have certain other health issues.
NizwaAges 13 years+ - NCT07491718Recruiting
MRI with manganese for takotsubo cardiomyopathy
This study uses a special MRI with a contrast agent called manganese to look at how the heart works in people with takotsubo cardiomyopathy (broken heart syndrome). It may help doctors understand why this condition happens and how to treat it better.
EdinburghAges 18 years+ - NCT07601867Recruiting
Dapagliflozin to improve heart function after bypass surgery
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
Pyatigorsk, Stavropol KrayAges 18 years+ - NCT07614230RecruitingPhase 4
SGLT2 drugs and heart artery health in diabetes
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Beijing, Beijing MunicipalityAges 18–78 - NCT06954090Enrolling by invitationPhase 4
Urine test to guide early treatment in type 2 diabetes
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
Herlev, Hajdú-BiharAges 18 years+
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 92 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.